Viatris Inc. announced that its President, Rajiv Malik, will be retiring as an executive of the Company effective April 1, 2024. Malik is a nearly 40-year pharmaceutical industry veteran who has been responsible for the day-to-day operations of Viatris since its inception, overseeing the Company's commercial business units, the Commercial Development, Medical, Information Technology and Quality functions, as well as Research & Development and Operations. His strategic vision and leadership played a key role in successfully integrating Viatris' legacy companies, Mylan and Upjohn, formerly a division of Pfizer Inc. With a unique leadership profile that combines his scientific, operational and commercial expertise, as well as his strong financial acumen, Malik has been a powerful asset for the Company.

Prior to Viatris, Malik served as president of Mylan, which he first joined in 2007 following the Company acquiring a controlling stake in Matrix Laboratories Limited, where he served as chief executive officer from 2005 to 2008. Malik will continue to serve on the Viatris Board of Directors.